Cullinan Oncology Inc Stock News

PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) h...

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025...

Cullinan Therapeutics, Inc. (NASDAQ:CGEM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Chad Messer Nadim Ahmed - President, CEO & Director Jeffrey Jones - Chief Medical Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morn...

Updated efficacy and safety data to be presented from the REZILIENT1 trial of zipalertinib from the cohort of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who were previously treated with amivantamab Preliminary clinical efficacy and safety data to be presented from the cohort of patients with uncommon n...

CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:

Cullinan (CGEM) Q2 R&D Jumps 68%

CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease

CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncology and autoimmune pipeline. However, their crown jewel right now is the late‑stage Zipalertinib. In my view, Zipalertinib is easily CGEM's main value driver for now. Its NDA filing is expected as early a...